Review




Structured Review

Eyegate Pharma epg-437 formulation
Epg 437 Formulation, supplied by Eyegate Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generalized+ordered+logit+formulation/epg+437+formulation/pm35008296-380-18-0
Average 90 stars, based on 1 article reviews
epg-437 formulation - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

Clinical Proteomics:

Article Title: New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma
Article Snippet: EyeGate company has developed a transscleral iontophoresis device and has completed Phase III clinical trials of EPG-437 formulation (dexamethasone formulation developed for iontophoresis administration) for anterior uveitis.

Article Title: New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.
Article Snippet: EyeGate company has developed a tra sscleral iontophoresis device an has completed Phase III cli ical trials of EPG-437 formulation (dexamethasone for ulation developed for iontophoresis administration) for anterior uveitis.

Article Title: New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma
Article Snippet: EyeGate company has developed a transscleral iontophoresis device and has completed Phase III clinical trials of EPG-437 formulation (dexamethasone formulation developed for iontophoresis administration) for anterior uveitis.

Formulation:

Article Title: New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma
Article Snippet: EyeGate company has developed a transscleral iontophoresis device and has completed Phase III clinical trials of EPG-437 formulation (dexamethasone formulation developed for iontophoresis administration) for anterior uveitis.

Article Title: New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.
Article Snippet: EyeGate company has developed a tra sscleral iontophoresis device an has completed Phase III cli ical trials of EPG-437 formulation (dexamethasone for ulation developed for iontophoresis administration) for anterior uveitis.

Article Title: New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma
Article Snippet: EyeGate company has developed a transscleral iontophoresis device and has completed Phase III clinical trials of EPG-437 formulation (dexamethasone formulation developed for iontophoresis administration) for anterior uveitis.



Similar Products

90
Eluru Municipal generalized ordered logit model formulations
Generalized Ordered Logit Model Formulations, supplied by Eluru Municipal, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generalized+ordered+logit+formulation/generalized+ordered+logit+model/10__1016_slash_j__amar__2024__100362-98-68-81
Average 90 stars, based on 1 article reviews
generalized ordered logit model formulations - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Eluru Municipal generalized ordered logit formulation
Generalized Ordered Logit Formulation, supplied by Eluru Municipal, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generalized+ordered+logit+formulation/generalized+ordered+logit+model/10__1016_slash_j__amar__2024__100351-74-12-26
Average 90 stars, based on 1 article reviews
generalized ordered logit formulation - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results